Table 1.
Demographic and clinical characteristics of patients in the three study groups
| Parameters | CRB | CHB | HCCB |
| n | 47 | 40 | 13 |
| Male: Female | 41:6 | 36:4 | 11:2 |
| (6.8:1) | (9:1) | (5.5:1) | |
| Mean age (yr) | 38.36 ± 4.13a | 37.65 ± 9.49 | 47.80 ± 18.70 |
| ALT (nKat/ L) | 1333 ± 483 | 1200 ± 579.5 | 908.5 ± 363.4 |
| AST (nKat/L) | 1152 ± 620 | 1283.6 ± 483 | 971.4 ± 360 |
| Total Bil. (μmol/ L) | 0.00016 ± 0.00012 | 0.00147 ± 0.00218 | 0.0028 ± 0.00032 |
| IgG anti-HBc | 91% | 94% | 93% |
| Risk factors | |||
| Transfusions | 27% | 27% | 24% |
| Tattoo | 7% | 5% | 6% |
| Operation | 8% | 4% | 6% |
| Intravenous drug abuse | 5% | 6% | 3% |
| Unknown | 53% | 58% | 61% |
| Genotype A | (8/47) 17% | (7/40) 17% | (1/13) 7.6% |
| Genotype Db | (38/47) 81% | (32/40) 80% | (11/13) 85% |
| Genotype A+D | (1/47) 2% | (1/40) 3% | (1/13) 7.6% |
| HBeAg +ve (%) | 77%a | 82%a | 51% |
| Sustained virological response to therapy | Genotype A: (2/ 7) 28.5% | ||
| Genotype D: (12/32) 37.5% (P = NS) |
a
P < 0.05 vs HCCB;
b
P < 0.01 vs Genotype A; NS: Not significant.